Rep. Robert Bresnahan, Jr. Sells Moderna, Inc. (NASDAQ:MRNA) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Moderna Stock Performance

Shares of MRNA stock traded down $0.08 during mid-day trading on Thursday, hitting $23.94. 1,789,462 shares of the stock were exchanged, compared to its average volume of 7,643,970. The stock has a market capitalization of $9.26 billion, a price-to-earnings ratio of -2.57 and a beta of 1.99. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The stock's fifty day simple moving average is $28.52 and its two-hundred day simple moving average is $36.08.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the prior year, the firm earned ($3.07) earnings per share. The company's quarterly revenue was down 35.3% on a year-over-year basis. On average, research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares in the last quarter. S Bank Fund Management Ltd bought a new stake in Moderna during the first quarter worth $25,000. Venturi Wealth Management LLC boosted its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna during the 4th quarter worth $37,000. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the 4th quarter worth $41,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several recent research reports. JPMorgan Chase & Co. cut their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Friday, March 21st. Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target on the stock. Morgan Stanley decreased their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Berenberg Bank increased their target price on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Finally, Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $53.95.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.